Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

• Status: Completed
• Trial end date: 2020-09-13
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CHA University
• Collaborator: Samil Pharmaceutical Co., Ltd.
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• IOP >/= 15mmHg and < 40 mmHg in each eye using Goldmann applanation tonometry at visit 2

• Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

• Patients with closed-angle, congenital glaucoma or secondary glaucoma caused by steroid drugs, etc.

• best-corrected visual acuity 20/80 or less

• Patients who have ongoing medical history of ocular inflammation

• central corneal thickness is not in between 470um and 591um.

• Patients who have received lacrimal duct procedure within the last 3 months or who have plans to have it.

• pregnant or nursing women